Autologous stem cell transplantation (ASCT) as consolidation therapy for patients with low-intermediate (LI) risk diffuse large B-cell lymphoma (DLBCL) and overexpression of bcl2 protein. Results of the first interim analysis of the GELA trial LNH98-B2
2004 ◽
Vol 22
(14_suppl)
◽
pp. 6505-6505
Keyword(s):
B Cell
◽